Infectious causes of cancer

Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver

Retrieved on: 
Thursday, June 3, 2021

Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
  • Enanta is also conducting research in SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir).

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Retrieved on: 
Wednesday, June 2, 2021

Small cell lung cancer comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the U.S., Dr. Kovach continued.

Key Points: 
  • Small cell lung cancer comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the U.S., Dr. Kovach continued.
  • The median survivalof patients with this especially aggressive type of lung cancer, even with current best therapy, is approximately nine months.
  • Because of such rapid disease progression, the therapeutic benefit of adding LB-100 to the standard treatment may be seenearlyon in this Phase 1b clinical trial.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.

Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OP

Retrieved on: 
Wednesday, June 2, 2021

The ASCO presentation coincides with the launch of HPV-SEQ as the newest CLIA validated assay in the Sysmex Inostics portfolio of ultra-sensitive SafeSEQ NGS panels.

Key Points: 
  • The ASCO presentation coincides with the launch of HPV-SEQ as the newest CLIA validated assay in the Sysmex Inostics portfolio of ultra-sensitive SafeSEQ NGS panels.
  • Sysmex Inostics has introduced HPV-SEQ, an ultra-sensitive blood-based liquid biopsy solution for identifying and accurately quantifying circulating HPV 16 and HPV 18 DNA in patients with HPV-related cancers.
  • Importantly, a high correlation was observed between dynamic changes in patients' cfHPV DNA levels and radiographic responses following induction therapy.
  • Sysmex Inostics, a Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators cost-effective and ultra-sensitive quantitative liquid biopsy solutions, OncoBEAM (digital PCR) and SafeSEQ (NGS).

Naveris' New Saliva Test Detects Head and Neck Cancer

Retrieved on: 
Wednesday, June 2, 2021

A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result.

Key Points: 
  • A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result.
  • The study results point to the potential for a significant improvement in early detection of the most common type of head and neck cancer, HPV-associated oropharyngeal squamous cell carcinoma.
  • Naveris patient-friendly saliva test has the potential to radically advance early detection of HPV-positive head and neck cancer, which has been growing rapidly among men in the United States.
  • NavDx is a liquid biopsy test that detects HPV-associated head and neck cancer earlier than is possible with imaging and is provided exclusively in the United States through the Naveris national reference CAP-accredited laboratory.

Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

Retrieved on: 
Wednesday, June 2, 2021

Arbutus will hold a conference call at 8:00 AM ET, Monday June 28, 2021 to discuss the new data being presented at EASL.

Key Points: 
  • Arbutus will hold a conference call at 8:00 AM ET, Monday June 28, 2021 to discuss the new data being presented at EASL.
  • The accepted abstracts include two oral presentations, one of which is a late breaker, and three poster presentations.
  • AB-729 inhibits viral replication and reduces all HBV antigens, including hepatitis B surface antigen in preclinical models.
  • Reducing hepatitis B surface antigen is thought to be a key prerequisite to enable reawakening of a patients immune system to respond to the virus.

Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

Retrieved on: 
Tuesday, June 1, 2021

HyperHEP B is the newest version of Grifols' current HBIG, HyperHEP B S/D, which is presently prescribed globally in over 20 countries.

Key Points: 
  • HyperHEP B is the newest version of Grifols' current HBIG, HyperHEP B S/D, which is presently prescribed globally in over 20 countries.
  • It is estimated that between 800,000 and 1.4 million people in the U.S. are currently infected with hepatitis B.
  • "HBIG for use in prophylaxis is an important treatment choice for our patients who are exposed to the hepatitis B virus.
  • Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after hepatitis B immune globulin (human) administration.

Evofem Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

Retrieved on: 
Tuesday, June 1, 2021

Evofem Biosciences, Inc., (NASDAQ:EVFM) is developing and commercializing innovativeproducts to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).

Key Points: 
  • Evofem Biosciences, Inc., (NASDAQ:EVFM) is developing and commercializing innovativeproducts to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).
  • The Company launched its first FDA-approved commercial product, Phexxi (lactic acid, citric acid and potassium bitartrate), inthe United StatesinSeptember 2020.
  • The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD .'
  • Phexxiis a registered trademark of Evofem Biosciences, Inc.

Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021

Viracta is a precision oncology company targeting virus-associated malignancies.

Key Points: 
  • Viracta is a precision oncology company targeting virus-associated malignancies.
  • Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma.
  • Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

Retrieved on: 
Thursday, May 27, 2021

FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Companys proprietary Versamune T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.

Key Points: 
  • FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Companys proprietary Versamune T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.
  • Because head and neck cancer is often diagnosed at later stages, treatment is often more difficult and more invasive.
  • There are exciting things happening in clinical research for head and neck cancer therapies, said Amanda Hollinger, Executive Director of HNCA.
  • In 2018, head and neck cancer surpassed cervical cancer as the most common HPV-attributed cancer in the United States.

Global Cholangiocarcinoma Market (2021 to 2028) - Featuring Incyte, QED Therapeutics and RenovoRx Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021

Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct.

Key Points: 
  • Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct.
  • The bile duct carries a fluid called bile, which is secreted in the liver and stored in the gall bladder.
  • There are two types of bile duct cancer intrahepatic bile duct cancer and extrahepatic bile duct cancer.
  • The collaboration intends to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer).